Ga-68 FAPI PET Before Immunotherapy

Prognostic Significance of Ga-68 FAPI PET Before Immunotherapy in Pleural Mesothelioma

Status

Recruiting

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT06451536

Acronym

FAPBI

Enrollment

Registered

2024-06-11

Start date

2024-04-30

Completion date

2025-04-30

Last updated

2024-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mesotheliomas Pleural

Brief summary

It is aimed to evaluate FAP expression and its success in predicting treatment response before immunotherapy used in the treatment of malignant mesothelioma with Ga68 FAPI PET/CT imaging, which allows in vivo evaluation of FAP expression, which is thought to be associated with immunosuppression and resistance to immunotherapy.

Detailed description

Patients diagnosed with pleural mesothelioma and planned for immunotherapy will be included in the study. Patients will undergo Ga68 FAPI PET/CT imaging within 10 days before the start of immunotherapy treatment, and SUVmax, SUVmean, metabolic tumor volume and total Ga68 FAPI uptake parameters will be obtained from the tumors. Following this, the routine treatment and follow-up of the patients will be carried out by their clinicians. It will be evaluated whether there is a correlation between treatment response and initial Ga-68 FAPI PET findings.

Interventions

DIAGNOSTIC_TESTGa-68 FAPI PET/CT

imaging of FAP expression of tumor before immunotherapy

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

DIAGNOSTIC

Masking

NONE

Intervention model description

prediction of immunotherapy response with Ga-68 FAPI PET

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Having a histopathologically confirmed diagnosis of * Pleural Mesolthelioma * Patients scheduled for immunotherapy with anti-PDL-1 and/or anti-CTLA-4 antibodies as first or second line therapy * Patients who gave informed consent form to participate in the study

Exclusion criteria

* ECOG\>2 * Patients who did not provide informed consent form to participate in the study

Design outcomes

Primary

Measure	Time frame	Description
Prediction of immune therapy response with Ga-68 FAPI PET	6. month after initiation of therapy	prediction of immunotherapy response with SUVmax measured with Ga-68 FAPI PET before immunotherapy

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026